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Abstract
Background and purpose—Post-operative SRS (stereotactic radiosurgery) for large brain
metastases is challenged by risks of radiation necrosis that limit SRS dose. Intraoperative
radiotherapy (IORT) is a potential alternative, however standard dose recommendations are
lacking.
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Methods and materials—Twenty consecutive brain metastases treated with post-operative SRS
were retrospectively compared to IORT plans generated for 10–30 Gy in 1 fraction to 0–5 mm by
estimating the applicator size and distance from critical organs using pre-operative and postoperative MRI. Additionally, 7 consecutive patients treated with IORT 30 Gy to surface were
compared to retrospectively generated SRS plans using the post-operative MRI to 15–20 Gy and
30 Gy in 1 fraction marginal dose.
Results—For the 20 resection cavities treated with SRS and retrospectively compared to IORT,
IORT from 10 to 30Gy resulted in lower or not significantly different doses to the optic apparatus
and brainstem. Comparatively for the 7 patients treated with IORT 30 Gy to retrospective SRS
plans to standard 15–20 Gy and 30 Gy marginal dose, IORT resulted in significantly lower doses
to the optic apparatus and brainstem. At a median follow-up of 6.2 months, 86% of patients treated
with surgery and IORT achieved local control and 0% developed radiographic or symptomatic
radiation necrosis.
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Conclusions—Critical organ dosimetry for IORT remains generally lower than that achieved
with single fraction SRS following resection of large brain metastases. We recommend 30 Gy to
surface as the preferred prescription, consistent with the dose recommendation for IORT in
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glioblastoma used in the ongoing INTRAGO-II phase-III trial. Early clinical outcomes appear
promising for surgery and IORT.
Keywords
Brain metastases; Stereotactic radiosurgery; GammaKnife; Intraoperative radiation; Resection
cavity

Introduction
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Multiple landmark clinical trials have established the importance of aggressive local therapy
via surgery and/or stereotactic radiosurgery (SRS) with the omission of whole brain
radiotherapy in sparing long-term neurocognitive effects for patients with brain metastases
[1–3]. Recent prospective data from RTOG 1270/NCCTG N107C comparing SRS to the
resection cavity versus whole brain radiotherapy, again highlighted the importance of SRS in
preserving neurologic function [4]. However, the preservation of neurocognition without a
compromise in overall survival came at a cost of worse local control. Due to risks of
radiation necrosis, SRS dose especially for large resection cavities is constrained to 12–20
Gy in 1 fraction with lower doses used with increasing resection cavity sizes [4]. However,
SRS remains a superior alternative to observation following the resection of brain
metastases, as 50–60% of patients observed after surgery alone will suffer local recurrence
[5]. Both trials reduced the SRS dose with increasing cavity size to reduce the risk of
necrosis, though this is contrary to the principle that greater tumor volume should require a
higher dose for local control. This dose reduction combined with difficulties in target
delineation of the resection cavity and challenges of tumor cell hypoxia in the post-operative
setting may have combined to account for the up to 20–40% rates of local failure [4, 5].
Thus, alternative strategies are warranted.
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Intraoperative radiotherapy (IORT) has been used as a potential alterative to SRS following
resection of large brain tumors [6–12]. IORT has advantages of eliminating challenges in
target definition, steep conformal dose delivery that may afford dose-escalation relative to
SRS, and increased patient convenience by integrating resection and radiotherapy into 1
procedure. A variety of techniques have been used for IORT in brain metastases including
low-energy photons and permanent low dose rate brachytherapy with 131Cs and 125I [6–8,
11, 12]. However, dose selection for low energy photon based IORT in brain tumors remains
largely empiric with doses ranging from 10 to 30 Gy in 1 fraction to varying prescription
depths of 0–5 mm [6–10]. Thus to help better guide the clinical application of IORT
following resection of large brain metastases, we aimed to compare the critical organ
dosimetry for varying prescription doses of IORT to patients treated with single fraction
SRS. We hypothesize that the combination of steep conformal dose fall-off and the
compression of the resection cavity inherent to IORT may allow for dose escalation beyond
the standard dose range of 12–20 Gy used for post-operative SRS with less dose to
surrounding critical organs.
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Materials and methods
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Following institutional review board approval, twenty consecutive brain metastases resection
cavities treated with Leksel GammaKnife® Perfexion™ (Elekta, Stockholm Sweden) SRS
from 2013 to 2017 were retrospectively reviewed. Patients with significant residual disease
greater than 2 mm in thickness that would have precluded IORT were excluded. There was
no exclusion by size, location, or number of metastases. SRS doses ranged from 12 to 22 Gy
in 1 fraction to the 50% isodose line. For SRS, the gross tumor volume (GTV) was defined
as the resection cavity plus any minimal residual tumor; GTV equaled the planning target
volume with no additional expansion routinely applied. Critical organ dosimetry was
retrospectively collected and compared to theoretical IORT plans generated using 50 kV Xrays on the INTRABEAM® 600 (ZEISS International, Jena, Germany). IORT plans were
generated using spherical applicators ranging from 1.5 to 5 cm for doses ranging from 10–30
Gy in 1 fraction prescribed to 0–5 mm from the applicator surface by estimating the
applicator size and distance from critical organs using a combination of pre-operative and
post-operative MR imaging. Figure 1 shows a case example of IORT for brain metastasis.
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Additionally, 7 consecutive patients treated with surgical resection followed by IORT using
Zeiss INTRA-BEAM® spherical applicator system to deliver 30 Gy to applicator surface for
large brain metastases from October 2017 to April 2018 were retrospectively reviewed.
Using the post-operative MRI, single fraction SRS plans were created for the
GammaKnife® Perfexion using GammaPlan v10.1 (Elekta, Stockholm, Sweden). SRS plans
were generated both for marginal doses of 15–20 Gy in 1 fraction prescribed to the 50%
isodose line as dictated by the resection cavity volume per NCCTG N107C dose guidelines
as well for 30 Gy marginal dose as used for IORT [4]. Critical organ dosimetry for IORT
was calculated using intraoperative measurements of the minimum distance to the respective
critical organ to the resection cavity using real time intraoperative neuro-navigation
(BrainLAB® Cranial Navigation, Munich Germany) (see Fig. 1).
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Statistical analyses were completed using IBM SPSS version 24 (SPSS Chicago, Illinois).
Mean maximal doses to optic chiasm, optic nerve, and brainstem as well as the volume of
brain receiving 12 Gy (V12Gy) were compared between SRS and IORT using two-sided
paired t tests. For patients with multiple metastases, including those with multiple resection
cavities, critical organ dosimetry was calculated for each resection cavity only without
contribution from other lesions. For SRS, the brain total V12Gy was the total intracranial
volume receiving 12 Gy as estimated from the skull contour [13]. For comparison, an
alternative definition of V12 (SRS V12Gy Minus GTV) was calculated using total V12Gy
volume minus the GTV volume [14]. For IORT, the V12Gy was conservatively calculated
using a spherical estimate of the V12Gy excluding the applicator volume, and thus does not
account for attenuation at high density interfaces such as the skull. A p < 0.05 was
considered significant for all analyses.

Results
Baseline patient characteristics for the 19 patients (20 resection cavities) treated with SRS
and retrospectively compared to IORT were as follows: median patient age was 60 [inter-
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quartile range (IQR): 49–62], RPA class 2 (IQR 2–2), and GPA class 2.0 (IQR 1–2). The
most common histology was non-small cell lung cancer. The median pre-operative maximal
tumor diameter was 3.4 cm (IQR 2.5–4.1), and median post-operative maximal resection
cavity diameter was 2.4 cm (IQR 1.6–2.7). The estimated IORT applicator median was 2.5
(IQR 2.5–3.9). The median planning target volume at the time of SRS was 7.2 cc (IQR 4.2–
9.2). The median marginal dose for SRS was 17.0 Gy (IQR 15.0–19.5) to the 50% isodose
line, with a corresponding median maximum dose of 34.0 Gy (IQR 30.0–39.0 Gy). The
mean maximal dose to optic chiasm, optic nerve, brainstem, and V12Gy were 0.50 Gy (IQR
0.23–0.68), 0.41 Gy (IQR 0.21–0.53), 2.44 Gy (IQR 0.34–2.56), and 19.74 cc (IQR 10.55–
24.67) respectively.
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As summarized in Table 1, IORT across the dose range of 10–30 Gy resulted in lower or not
statistically significantly different mean maximal doses to optic chiasm, optic nerve, and
brainstem. The mean total V12Gy was lower or not statistically significantly different
comparing IORT from 10 to 20 Gy (see Table 1). For IORT doses of 30 Gy to the applicator
surface, the mean total V12Gy was statistically significantly higher than SRS (28.94 cc
± 21.78 versus 19.74 cc ± 15.35, p = 0.02). When splitting data by applicator size ≥ 4 cm, no
significant differences in mean total V12Gy were noted comparing IORT 30 Gy to the
applicator surface versus SRS for applicators < 4 cm (18.91 cc ± 9.76 versus 16.41 cc
± 9.04, p = 0.36); while for those ≥ 4 cm the mean total V12Gy remained significantly
higher for IORT 30 Gy to the applicator surface versus SRS (59.03 cc ± 20.78 versus 29.74
cc ± 25.83, p < 0.01). When using the alternative SRS definition of V12Gy Minus GTV,
significantly higher doses of V12Gy were noted for IORT prescriptions of 30 Gy to surface,
16 Gy to 2 mm, and 18 Gy to 2 mm compared to SRS; with no significant differences for
IORT prescriptions of 20 Gy to surface, 10 Gy to 5 mm, and 14 Gy to 2 mm (see Table 1).
When splitting data by applicator size ≥ 4 cm with SRS definition of V12Gy Minus GTV,
IORT prescriptions of 16 Gy to 2 mm and 18 Gy to 2 mm were not significantly different
than SRS for applicators < 4 cm (10.45 cc ± 5.09 versus 10.18 ± 5.39, p = 0.85) and (13.46
cc ± 6.54 versus 10.18 ± 5.39, p = 0.06) respectively; while IORT prescription of 30 Gy to
surface was statistically higher even for applicators < 4 cm (18.91 cc ± 9.76 versus 10.18
± 5.39, p < 0.01). For applicators ≥ 4 cm and using the V12Gy Minus GTV definition for
SRS, IORT to 16 Gy to 2 mm, 18 Gy to 2 mm, and 30 Gy to surface was consistently
statistically significantly higher than SRS (30.63 cc ± 7.74 versus 15.71 ± 8.73, p < 0.01),
(39.50 cc ± 10.24 versus 15.71 ± 8.73, p < 0.01), and (59.03 cc ± 20.28 versus 15.71 ± 8.73,
p < 0.01), respectively.
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For the 7 patients treated with IORT 30 Gy to surface for large brain metastases, the median
patient age was 67 (IQR 44–75), median RPA class was 2 (IQR 2–2), and median SRS gross
tumor volume was 15.58 cc (IQR 6.18–19.36). The most common primary histology was
non-small cell lung cancer in 71%. Applicator size ranged from 1.5 to 3.0 cm. As
highlighted in Fig. 2, the mean V12Gy volume for IORT with SRS definition of V12 total
was 18.79 cc ± 10.37 versus 25.78 cc ± 10.51 for SRS marginal doses of 15–20 Gy, p =
0.09, and 65.24 cc ± 33.58 for SRS doses of 30 Gy, p < 0.01. The mean V12Gy volume for
IORT with SRS definition of V12 Minus GTV was 18.79 cc±10.37 versus 12.84 cc±3.78 for
SRS marginal doses of 15–20 Gy, p = 0.14, and 52.29 cc±26.68 for SRS doses of 30 Gy, p <
0.01. The mean maximal dose for the brainstem for IORT was 0.34 Gy ± 0.46 versus 0.97
J Neurooncol. Author manuscript; available in PMC 2019 November 01.
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± 0.75 for SRS marginal doses of 15–20 Gy, p < 0.01, and 1.82 Gy ± 1.56 for SRS doses of
30 Gy, p = 0.01. The mean maximal dose for the optic apparatus for IORT was 0.26 Gy
± 0.25 versus 0.60 ± 0.38 for SRS marginal doses of 15–20 Gy, p = 0.04, and 1.13 Gy ± 0.71
for SRS doses of 30 Gy, p < 0.01.
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At a median follow-up of 6.2 months (IQR 3.6–8.8), 86% of the patients treated with IORT
remain alive living and well and 0% have developed radiographic or symptomatic radiation
necrosis from IORT. Figure 3 shows an example of IORT noting the potential clinical
advantages in terms of radiation injury reactions and associated bleeding of adjacent
hemorrhagic metastases which developed symptomatic hemorrhage despite SRS and whole
brain irradiation. The 1 patient who expired, died from cardiopulmonary arrest. One patient
developed local failure after surgery and IORT at 8.8 months following surgery and IORT
for a dural-based metastasis secondary to endometrial cancer (see Fig. 4); thus the crude
local control rate was 86%.

Discussion
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The recently published RTOG 1270/NCCTG N107C highlighted the importance of postoperative SRS following surgical resection of brain metastases in preservation of
neurocognitive quality of life over post-operative whole brain irradiation, at the expense of
suboptimal local control [4]. IORT represents a potential alternative to SRS with a steep
conformal dose fall-off inherent to the low-energy 50 kV X-ray source. Clinically, the
compression of the resection cavity maximizes dose to the target while obviating challenges
in SRS target definition, and increases patient convenience over SRS. Furthermore, from a
radiobiological perspective, immediate IORT may potentially improve local control by
counteracting the tumor cell proliferation caused by the surgical manipulation of the
microenvironment [15]. However, the doses used in the IORT brain tumor literature have
varied significantly from 10 to 30 Gy prescribed to 0–5 mm from the applicator surface [6–
10]. Here, we retrospectively compared the dose to critical organs and V12Gy for IORT
versus that which was achieved with single fraction SRS. As summarized in Table 1, IORT
across the dose ranges reported in the literature resulted in lower or not statistically
significantly different doses to critical organs than that achieved with SRS; with optic
chiasm doses generally 1/2, optic nerve 1/2 to 1/3rd, and brainstem 1/2 to the same as the
SRS dose. This retrospective comparison was then validated in a preliminary cohort of 7
consecutive patients treated with IORT 30 Gy to the applicator surface compared to
retrospective created SRS plans to margins doses of 15–20 Gy and 30 Gy (see Fig. 2); again
with 1/2 to 1/3rd the dose to optic apparatus and brainstem with IORT compared to SRS 15–
20 Gy marginal dose and a significant reduction of 1/4 to 1/6th the dose compared to SRS
30 Gy marginal dose. V12Gy doses were generally comparable from clinical SRS to IORT
10–30 Gy to 0–5 mm depth except for the largest applicators ≥4 cm, comparable for IORT to
30 Gy clinical cohort to SRS marginal doses of 15–20 Gy, and significantly lower for IORT
to 30 Gy clinical cohort to SRS marginal doses of 30 Gy. Clinically, the early outcomes
following surgery and IORT appear to promisingly validate these dosimetric comparisons
with 86% local control and 0% radiographic or symptomatic radiation necrosis.

J Neurooncol. Author manuscript; available in PMC 2019 November 01.
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IORT has been used for decades in the treatment of brain metastases, a needle applicator
mounted to a stereotactic frame was placed into the center of the tumor prior to resection,
using doses ranging from 10 to 20 Gy to 2 mm depth, local control rates ranged from 81 to
100% for metastases with radiation necrosis rates of < 5% [7, 16, 17]. Promising results for
the use of more recently developed spherical applicator systems better able to conform to the
resection cavity than needle applicators from the TARGIT-A randomized trial using 20 Gy
to surface in early-stage breast cancer has brought renewed interest to the use of IORT [18].
Investigators from Cleveland Clinic recently published a phase I feasibility trial using the
INTRABEAM delivery system and the associated spherical applicator system for resected
brain metastases [6]. Using a standardized dose of 14 Gy to 2 mm “chosen on the basis of
previous experience reported in the literature and on experience with SRS,” IORT resulted in
a 30% crude local failure rate at a mean of 9 months post-IORT. Conversely, high rates of
radiation necrosis were reported in a phase I dose-escalation study for recurrent (often
previously-irradiated) pediatric brain tumors, where 10 Gy prescribed to 5 mm depth
resulted in a 21% rate of radiation necrosis [9]. An ongoing international phase III clinical
trial (INTRAGO-II, NCT02685605) is investigating the potential role of IORT for
glioblastoma, where 30 Gy to the applicator surface is prescribed prior to 60 Gy of
conventionally fractionated external beam radiotherapy. The dose of 30 Gy to surface was
selected based on the preceding phase I/II dose-escalation study from the same group [10].
The results presented here-in would support that 30 Gy to the applicator surface provides a
dose to critical organs lower than or comparable to that achieved with SRS to standard
marginal doses, and except for large applicator diameters, ≥ 4 cm, achieves a comparable
V12Gy. Clinically the use of 30 Gy to surface IORT resulted in comparably lower rates of
local failure at 14% with 6-months follow-up and 0% radiation necrosis. With the
suboptimal local control noted with 14 Gy to 2 mm, the higher rates of radiation necrosis
noted with 10 Gy to 5 mm, and the established safety of 30 Gy to surface from the
glioblastoma literature, we recommend the use of 30 Gy to surface when applying IORT for
brain metastases recognizing that this will achieve comparable if not lower critical organ
dosimetry to standard marginal doses for SRS. For larger tumors requiring applicators ≥ 4
cm, we recommend decreasing the dose to 20 Gy to surface to conservatively maintain a
volume of normal brain receiving 12 Gy that is comparable to that achieved clinically with
SRS.
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A surface based prescription for IORT is supported by multiple pathology series which
document that an infiltration depth of 2 mm is described as deep [19–21]. Considering that
IORT prescribed to 30 Gy at the applicator surface would provide an estimated 19.9–23.5
Gy at 2 mm depth; these pathology data would support that any unresected microscopic
tumor infiltration would receive sufficient toxic tumor dose. Eventually as highlighted by the
1 recurrence noted herein for a dural-based endometrial cancer metastasis, ideally IORT
prescriptions could be modulated as specified by tumor pathology recognizing the
heterogeneity in growth and infiltration by various tumor subtypes and the potential impact
on local failure [22].
A number of alternative techniques to low energy X-ray based IORT have been described for
the treatment of brain metastases including permeant low dose rate brachytherapy with 125I
and 131Cs as well as temporary implants with balloon based delivery of aqueous 125I [6–8,
J Neurooncol. Author manuscript; available in PMC 2019 November 01.
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11, 12]. Low energy X-ray based IORT has advantages of avoiding concerns of seed
migration, no need for special handling precautions of radioactive sources, and eliminates
the complexity of seed placement thereby reducing anesthesia time and potential reoperation for seed removal in temporary brachytherapy implants. Potential disadvantages
compared to brachytherapy forms of IORT include the spherical applicator system is not
able to be customized to conform to irregularly shaped cavities and theoretical concerns for
trauma to normal brain tissue with spherical applicator placement or if shifts were to occur
during placement.

Author Manuscript
Author Manuscript

This study is limited by retrospective design. Applicator diameter was estimated based on a
combination of preoperative and post-operative MRI and thus may not account for true
applicator size with the intraoperative compression often clinically afforded by IORT.
Reliable dosimetric correlates to predict risks of radiation necrosis for IORT are currently
lacking, thus it is possible that the V12Gy may not correlate with rates of radiation necrosis
following IORT. Furthermore, it is difficult to directly compare the V12Gy for SRS versus
IORT. For IORT, the high dose region beyond the applicator surface that interfaces with the
resection cavity thickness could not be reliably measured and thus any cavity thickness or
residual tumor was not excluded from the calculated V12Gy for IORT; nor was the dose
extending into air beyond the applicator entrance or attenuated at the skull interface.
Nonetheless, using either V12Gy calculated as a total volume or V12Gy Minus GTV for
SRS results were generally consistent; IORT V12Gy was comparable or lower except for the
highest dose range with applicators ≥ 4 cm. SRS target definition here-in did not include a 2
mm margin as recommended by some when target resection cavities and thus the doses to
critical organs and V12Gy may have been lower here than in other SRS experiences [19, 23].
However, even in prospective clinical trials the margin for post-operative SRS for brain
metastases remains variable [4, 5]. Other critical organs were not compared in this study
such as the scalp, ocular structures (such as lens or retina), or cochlea. Due to the low
penetration through high density material such as the skull of the 50 kV X-rays used in
IORT, scalp, ocular structures, or cochlea dose is always assumed to be lower than SRS [20,
24]. Furthermore, the relative biologic effectiveness of IORT versus SRS beam profiles were
not accounted for, wherein at distances greater than 1–1.5 cm (such as was the case for most
of the critical organs studied) the decreased relative biologic effectiveness of IORT 50 kV Xrays may further reduced the effective dose to critical organs and volume of normal brain
receiving 12 Gy relative to that measured here-in [21, 25]. Continued study is needed to best
define the optimal application and dose selection for low energy X-ray IORT in the
treatment of brain metastases.
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Conclusions
IORT prescribed 30 Gy to the applicator surface provides lower doses to the optic apparatus
and brainstem than that clinically achieved with SRS. The V12Gy is a function of applicator
size, and when applicator size exceeds ≥ 4 cm, 30 Gy to surface results in mean doses of
V12Gy higher than that clinically achieved with SRS. Consistent with the dose
recommendation for IORT in glioblastoma used in the ongoing INTRAGO-II prospective
randomized trial, we recommend 30 Gy to surface as the preferred prescription dose for
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IORT in brain metastases as supported by the narrow range of infiltration reported in
pathologic series and the promising early clinical outcomes reported herein.
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Fig. 1.

Case example of the spherical applicator used for IORT for brain tumor patient
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Fig. 2.

Volume of brain receiving 12 Gy as a function of spherical applicator size and dose
prescription. IORT intraoperative radiotherapy, Gy gray, V12 volume of brain receiving 12
Gy
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Fig. 3.
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Clinical example of the potential favorable outcomes for IORT in reducing radiation injury
reactions. a Large left frontal brain metastasis secondary to melanoma treated with surgery
and IORT 30 Gy to the applicator surface. b MRI follow-up 9 months after IORT, notice the
stable left frontal resection cavity compared to adjacent smaller metastases which were
treated with SRS and WBRT with interval associated hemorrhage and radiation injury
reaction. Finally compare the outcomes for the left frontal resection cavity from panels a, b
to the outcome of a left temporoparietal metastases in panels c, d now with significant posttreatment changes and symptomatic mass effect on the adjacent brainstem
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Fig. 4.
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Clinical example of local failure after IORT for a dural-base endometrial cancer brain
metastasis. a Large left parietal brain metastasis treated with surgery and IORT 30 Gy to the
applicator surface. b Stable resection cavity 2.5 months post-IORT. c Stable to slight
increase in enhancement in resection cavity at 5.5 months post-IORT. d Local recurrence at
8.8 month post-IORT
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19.74 ± 15.35
11.56 ± 6.59

V12Gy minus GTV, cc

2.58 ± 6.63 p = 0.83
28.94 ± 21.78 p = 0.02
28.94 ± 21.78 p < 0.01

12.78 ± 10.05 p = 0.48

0.22 ± 0.18 p = 0.01

0.15 ±0.12 p < 0.01

12.78 ± 10.05 p = 0.01

0.27 ± 0.18 p = 0.02

0.18 ± 0.12 p < 0.01

1.71 ± 4.42 p < 0.01

IORT 30 Gy to 0 mm

IORT 20 Gy to 0 mm

13.17 ± 7.40 p = 0.26

13.17 ± 7.40 p = 0.03

1.82 ± 4.75 p = 0.04

0.16 ± 0.14 p < 0.01

0.19 ± 0.13 p < 0.01

IORT 10 Gy to 5 mm

11.06 ± 7.45 p = 0.72

11.06 ± 7.45 p < 0.01

1.66 ± 4.31 p = 0.01

0.15 ± 0.12 p < 0.01

0.17 ± 0.12 p < 0.01

IORT 14 Gy to 2 mm

15.49 ± 10.59 p = 0.04

15.49 ± 10.59 p = 0.11

1.90 ± 4.93 p = 0.09

0.17 ± 0.14 p < 0.01

0.20 ± 0.13 p < 0.01

IORT 16 Gy to 2 mm

SRS stereotactic radiosurgery, IORT intraoperative radiotherapy, Gy gray, V12 volume of brain receiving 12 Gy, Cc cubic centimeters, GTV gross tumor volume

2.44 ± 4.35

Total V12Gy, cc

0.41 ± 0.30

Max dose to optic nerve, Gy

Max dose to brainstem, Gy

0.50 ± 0.43

Max dose to optic chiasm,
Gy

SRS

Mean dose ± standard deviation

Critical organ dose comparison for stereotactic radiosurgery versus varying intraoperative radiotherapy doses

19.97 ± 13.69 p = 0.02

19.97 ± 13.69 p = 0.93

2.14 ± 5.54 p = 0.45

0.19 ± 0.16 p < 0.01

0.22 ± 0.15 p = 0.01

IORT 18 Gy to 2 mm
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